1,2,3,4- tetrahydro- 1- (phenylmethyl)isoquinoline

structure given in first source

Also Known As:

1,2,3,4-tetrahydro-1-(phenylmethyl)isoquinoline hydrochloride; 1,2,3,4-tetrahydro-1-(phenylmethyl)isoquinoline, (+-)-isomer; 1,2,3,4-tetrahydro-1-(phenylmethyl)isoquinoline, (R)-isomer; 1,2,3,4-tetrahydro-1-(phenylmethyl)isoquinoline, (S)-isomer; 1-benzyl-1,2,3,4-tetrahydroisoquinoline; 1BnTIQ; S49 isoquinoline

Networked: 20 relevant articles (0 outcomes, 4 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Isoquinolines: 34
      - Tetrahydroisoquinolines: 44
        1,2,3,4-tetrahydro-1-(phenylmethyl)isoquinoline: 20

Experts

1.	Antkiewicz-Michaluk, Lucyna: 4 articles (04/2016 - 01/2009)
2.	Romańska, Irena: 3 articles (04/2016 - 01/2009)
3.	Wąsik, Agnieszka: 3 articles (04/2016 - 01/2014)
4.	Kotake, Yaichiro: 3 articles (01/2014 - 11/2002)
5.	Ohta, Shigeru: 3 articles (01/2014 - 02/2005)
6.	Ebadi, Manuchair: 3 articles (05/2004 - 06/2003)
7.	Shavali, Shaik: 3 articles (05/2004 - 06/2003)
8.	Michaluk, Jerzy: 2 articles (04/2016 - 10/2014)
9.	Kajta, Małgorzata: 2 articles (10/2014 - 01/2014)
10.	Ohta, S: 2 articles (01/2003 - 07/2001)

Related Diseases

1.	Parkinsonian Disorders (Parkinsonism) 04/01/2016 - "The chronic administration of 1BnTIQ induced parkinsonism in primates, and this effect might be associated with idiopathic PD. " 02/27/2006 - "Previous work has established that 1-benzyl-1,2,3,4-tetrahydroisoquinoline (1-BnTIQ) causes a parkinsonian syndrome in rats. " 10/11/1996 - "This result suggested that 1BnTIQ may induce parkinsonism in humans. " 10/11/1996 - "1-Benzyl-1,2,3,4-tetrahydroisoquinoline hydrochloride (1Bn TIQHCl) (22 mg/kg per day) was subcutaneously injected into a monkey, Macaca fascicularis for 66 days to investigate its acute and chronic effects Parkinsonism like motor symptoms appeared, and the acute toxicity was stronger than the chronic toxicity. " 01/17/2003 - "1-Benzyl-1,2,3,4-tetrahydroisoquinoline (1-BnTIQ) and TIQ are endogenous substances inducing bradykinesia, one of the symptoms of parkinsonism, in rodents and primates, and 2-methyl-TIQ is postulated to be an active form of TIQ. "
2.	Neuroblastoma 01/01/2014 - "We previously reported that 1BnDIQ is more toxic than 1BnTIQ in cytotoxicity study in SH-SY5Y neuroblastoma cells. " 09/01/2010 - "The polyubiquitinated tubulin beta level in human neuroblastoma SH-SY5Y cells was reduced in the presence of 1BnTIQ, even at concentrations as low as those detected in parkinsonian CSF. "
3.	Neurodegenerative Diseases (Neurodegenerative Disease) 01/01/2014 - "Summarizing the studies, we suggest that 1BnTIQ is a rather weak endogenous neurotoxin; however, it should be taken into account that in higher μmoles concentrations, it can initiate apoptosis in the central nervous system and may be involved in the etiopathology of neurodegenerative diseases. "
4.	Parkinson Disease (Parkinson's Disease) 01/01/2009 - "Because 1BnTIQ is an endogenous compound, it may be one of the factors responsible for idiopathic Parkinson's disease." 02/01/2005 - "We suggest that 1BnTIQ may be related to the idiopathic Parkinson's disease. " 05/15/2004 - "The levels of 1BnTIQ in cerebrospinal fluid of patients with Parkinson's disease (PD) were reported to be three times higher than those in control subjects. " 01/01/2003 - "1-Benzyl-1,2,3,4-tetrahydroisoquinoline is specifically increased in the cerebrospinal fluid of patients with Parkinson's disease and induces parkinsonian features in the monkey and mouse. " 12/01/1995 - "We suggest that 1BnTIQ may be related to the idiopathic Parkinson's disease."
5.	Hypokinesia (Bradykinesia) 01/17/2003 - "1-Benzyl-1,2,3,4-tetrahydroisoquinoline (1-BnTIQ) and TIQ are endogenous substances inducing bradykinesia, one of the symptoms of parkinsonism, in rodents and primates, and 2-methyl-TIQ is postulated to be an active form of TIQ. " 07/13/2001 - "We administered 1-benzyl-1,2,3,4-tetrahydroisoquinoline (1-BnTIQ; 80 mg/kg, i.p.), an endogenous neurotoxin known to cause bradykinesia, the Parkinson's disease-like symptom, in order to obtain biochemical and pathological evidence of behavioral abnormalities. "

Related Drugs and Biologics

1.	Neurotoxins
2.	Selegiline (E250)
3.	Monoamine Oxidase (MAO)
4.	Dopamine (Intropin)
5.	1,2,3,4- tetrahydro- 1- (phenylmethyl)isoquinoline
6.	Amines
7.	alpha-Synuclein
8.	1- Methyl- 4- phenyl- 1,2,3,6- tetrahydropyridine (MPTP)
9.	Tubulin
10.	Proteins (Proteins, Gene)

Related Therapies and Procedures

1.	Therapeutics